Insider Buys Spark Optimism for Leap Therapeutics Stock

Insider Buying Sparks Optimism at Leap Therapeutics

On March 13, 2026, Leap Therapeutics’ key insider, Dietz Thomas John, completed a purchase of 104,500 shares of the company’s common stock, increasing his stake to 152,500 shares. The transaction followed a 1‑for‑1 settlement of a similarly sized restricted‑stock‑unit (RSU) grant, underscoring the executive’s active participation in the equity plan. With the share price at $0.79, the trade represents a modest outlay but a clear vote of confidence, especially in a market that has seen Leap’s stock tumble to $0.70 from its $3.70 52‑week high.

Market Significance of Insider Activity

The insider buy, coupled with a strong positive sentiment score (+3) and a 61 % communication buzz, signals that those closest to the company’s strategic direction are bullish. Three other senior officers—Mirabelli, Schilsky, and Cavanaugh—each recorded multiple buy‑side transactions on the same day. Even as Leap’s price remains below its 52‑week low, the surge in insider activity suggests management believes the company’s dual‑track strategy—advancing its Phase 2 sirexatamab program while expanding its privacy‑technology portfolio—will translate into upside. For investors, the pattern hints that the current valuation may be undervalued relative to the pipeline and digital‑asset upside, making the stock an attractive entry point for long‑term holders.

Profile of Dietz Thomas John

Thomas John’s insider history shows a consistent appetite for equity. He has repeatedly purchased shares (83,000 in December 2025, 104,500 in March 2026) and settled RSU grants that vest immediately. His trading is largely buy‑heavy, with only a few sales that appear to be RSU vesting events rather than market‑driven dispositions. This behavior indicates a long‑term commitment to Leap’s growth trajectory. In the biotech sector, such a pattern often correlates with a belief in the clinical pipeline and a willingness to weather short‑term volatility.

Clinical and Digital Upside

With Leap’s Phase 2 data showing promising efficacy in high‑DKK1 patients, and its Zcash‑based treasury generating unrealized gains, the company has two engines of potential upside. The recent insider buys reinforce the narrative that the management team sees significant upside and is willing to stake more equity on the outcome. For investors, the current price offers a discount to the 52‑week low and a clear signal that insiders remain optimistic—an encouraging sign for those considering a long‑term position in Leap Therapeutics.

Insider Transaction Summary